This article first appeared on GuruFocus. Novo Nordisk (NVO, Financials) is getting another data point for its oral Wegovy program, with real-world study suggesting that those who recently gained weight can get higher weight-loss effects from the medication.The observational study involved more than 3,000 patients who had not previously used GLP-1 medications. Those who had gained weight in the past five years were more likely to be super-responders, meaning they lost at least 10 percent of their body weight.By day 60, the super-responders had lost an average of 7.2% of their body weight, and by day 90, they had lost 11.4%. The group also had higher reductions in blood pressure than people who lost less weight.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.